<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00248963</url>
  </required_header>
  <id_info>
    <org_study_id>0858A2-315</org_study_id>
    <nct_id>NCT00248963</nct_id>
  </id_info>
  <brief_title>Study Evaluating Levonorgestrel and Ethinyl Estradiol in Oral Contraception</brief_title>
  <official_title>A Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 Mg and Ethinyl Estradiol 20 Mg in a Continuous 28-Day Regimen for Oral Contraception Versus a Cyclic 21-Day Regimen Oral Contraceptive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wyeth is now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wyeth is now a wholly owned subsidiary of Pfizer</source>
  <brief_summary>
    <textblock>
      To evaluate the contraceptive efficacy of an oral contraceptive containing a combination of
      LNG 90 mg/EE 20 mg in a continuous-use regimen and to evaluate the safety compared to LNG 100
      mg/EE 20 mg for 21 days followed by a 7-day hormone-free interval in a cyclic regimen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <completion_date>October 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Educational/Counseling/Training</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the contraceptive efficacy of an OC containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen and the safety compared to LNG 100 mg/EE 20 mg for 21 days followed by a 7-day hormone-free interval in a cyclic regimen</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects on vaginal bleeding profile, hemostatic balance, lipid, carbohydrate, bone metabolism measures, hemoglobin levels, discontinuation rates, compliance with respect to pill taking, subject satisfaction</measure>
  </secondary_outcome>
  <enrollment>600</enrollment>
  <condition>Oral Contraceptive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy women aged 18 to 49 years who are willing to rely upon a combination birth
             control pill as their only method of contraception.

          -  Women must be sexually active and at risk for becoming pregnant.

          -  Women must have had regular (21- to 35- day) menstrual cycles for the 3-month period
             preceding study visit 1.

        Exclusion Criteria:

          -  High blood pressure

          -  Age greater then 34 and smoking more than 15 cigarettes per day.

          -  Depression requiring hospitalization or associated with suicidal ideation within the
             last 3 years.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</affiliation>
  </overall_official>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2005</study_first_submitted>
  <study_first_submitted_qc>November 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2005</study_first_posted>
  <last_update_submitted>May 17, 2006</last_update_submitted>
  <last_update_submitted_qc>May 17, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2006</last_update_posted>
  <keyword>Oral Contraceptive</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

